Table 4.
Clinical characteristics and minimum inhibitory concentrations (MIC) of patients with resistant species during the study period.
| No. | Year | Age | CBSI Species | Underlying Condition | Anti-fungal Prophylaxis | Antibiotics Exposure | Fluconazole | Caspofungin | Micafungin |
|---|---|---|---|---|---|---|---|---|---|
| MIC (mg/L) | |||||||||
| 1 | 2006 | 3 years | C. parapsilosis | Short bowel syndrome, TPN | no | yes | 8 | 1 | - |
| 2 | 2007 | 3 years | C. albicans | Heart transplant | no | yes | ≤0.12 | 0.5 | - |
| 3 | 2007 | 5 months | C. lusitaniae | Short bowel syndrome, TPN | no | no | 32 | 0.5 | - |
| 5 | 2013 | 8 years | C. glabrata | Intestinal failure, megabladder, TPN | no | no | 2 | 0.25 | 0.25 |
| 6 | 2014 | 9 years | C. glabrata | Intestinal failure, megabladder, TPN | Amphotericin B | no | 4 | 0.5 | 1 |
| 7 | 2014 | 21 years | C. glabrata | Cystic fibrosis, lung transplant | Voriconazole | yes | 64 | 0.03 | 0.016 |
| 8 | 2015 | 7 years | C. lusitaniae | Cystic fibrosis | no | yes | 16 | 0.12 | 0.06 |
TPN: Total parenteral nutrition; numbers 5 and 6 correspond to the same patient. In bold, resistant strains. For the C. albicans strain, in bold, intermediate susceptibility.